UK markets close in 5 hours 8 minutes

  • FTSE 100

    6,908.75
    +13.46 (+0.20%)
     

  • FTSE 250

    22,211.89
    +126.16 (+0.57%)
     

  • AIM

    1,257.25
    +11.62 (+0.93%)
     

  • GBP/EUR

    1.1543
    -0.0028 (-0.24%)
     

  • GBP/USD

    1.3910
    -0.0022 (-0.16%)
     

  • BTC-GBP

    38,922.82
    -1,282.13 (-3.19%)
     

  • CMC Crypto 200

    1,253.16
    -9.80 (-0.78%)
     

  • S&P 500

    4,173.42
    +38.48 (+0.93%)
     

  • DOW

    34,137.31
    +316.01 (+0.93%)
     

  • CRUDE OIL

    61.05
    -0.30 (-0.49%)
     

  • GOLD FUTURES

    1,788.60
    -4.50 (-0.25%)
     

  • NIKKEI 225

    29,188.17
    +679.62 (+2.38%)
     

  • HANG SENG

    28,755.34
    +133.42 (+0.47%)
     

  • DAX

    15,289.59
    +93.62 (+0.62%)
     

  • CAC 40

    6,262.27
    +51.72 (+0.83%)
     
Analysis :

What the European Super League's collapse means for JP Morgan

The European Super League is dead on arrival but the impact of the aborted project will still leave a mark on those involved

Long-term investing: will the FTSE 100 rally as optimism grows?

Kirsteen Mackay
·3-min read
Hand holding pound notes
Hand holding pound notes

I want to secure my financial future and I think long-term investing is the answer. That’s because over time, good-quality companies reward shareholders and the compounded gains can be significant. The first place I look is the FTSE 100, with its international focus and well-established businesses. Rather than trying to time the market, I regularly invest and try not to worry about the ups and downs. Here’s why I think stock market investing is appealing.

FTSE 100 resilience

With Brexit finally done, after an epic four-year journey, the UK economy is breathing a sigh of relief, despite short-term obstacles. The lockdowns are a huge inconvenience, but with the vaccine rollout under way, investors are feeling hopeful that the temporary disruption will make way for a much stronger future.

Despite a hopeful start to the year, the FTSE 100 has bumped along with no real momentum. However, I believe that’s sure to change once the economy reopens for real. Of course, none of us can be sure that this lockdown will be the last. But with regions emerging gradually and full steam ahead on vaccine rollout, I think there’s reason to be hopeful.

In any case, I think it’s vital to remember the FTSE 100 contains many top-quality companies that will ride out the Covid-19 storm and still be standing far into the future. That’s why I’m happy to invest a regular sum into my Stocks and Shares ISA each month and simply leave it to grow.

Pound-cost-averaging

If I invest in the same stock or fund each month, this is known as dollar-cost-averaging or pound-cost-averaging. That’s because I’m not timing the market specifically when the price is low, I’m simply committing to buy shares on a set date each month. This means I sometimes pay more or less depending on market sentiment, but over time, the price paid averages out.

Emotional risk in long-term investing

Long-term investing can offer a slow and steady road to riches. Billionaire investors like Warren Buffett and Joel Greenblatt follow a value investing strategy that’s paid off handsomely. But sticking to it is easier said than done. Extreme market volatility can scare investors into making emotionally charged decisions. Either selling at an unnecessary loss or buying duds because they’ve fallen so fast and look cheap.

To get past that, I try to focus on the bigger picture, historically, stocks go up longer than they go down. As long as I’ve picked strong businesses, then there’s no reason to panic when market sentiment plummets.

Compounding raises investment value

If I invest £200 a month at a 5% annual interest rate, then after 20 years I’ll have over £81,000. That’s a nice sum to look forward to. If I can invest more, achieve a higher rate of return and leave it for a longer period, then the compounding effect will be much greater. Of course, I always run the risk that my investment could go down as well as up.

With consumer sentiment rising, confidence in the stock market is growing too. I think there’s good reason to believe the FTSE 100 will rally once we bring the pandemic under control and the country reopens. Before, during and after I’ll happily continue investing towards a brighter financial future using pound-cost-averaging and a long-term investing strategy.

The post Long-term investing: will the FTSE 100 rally as optimism grows? appeared first on The Motley Fool UK.

More reading

Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Motley Fool UK 2021

Latest stories

  • Bingham eyeing second Crucible crown after thrilling opening-round win

    Stuart Bingham believes he can make a serious run at a second Crucible title after “one of the best 70 breaks in World Championship history” helped him reach the second round.

  • How to tell when you've been bitten by a horsefly

    Treating a horsefly bite is similar to treating any other insect bite, but they are slightly more likely to become infected.

  • Fan outrage at Super League ‘the strongest message’ says Mikel Arteta

    The Arsenal boss has received a personal apology from the club’s owners.

  • Coronavirus no longer leading cause of death in England and Wales

    Office for National Statistics data shows it caused 9.2% of deaths in England and 6.3% in Wales in March.

  • Russia accuses Czechs of hysteria, warns against spy row escalation

    Russia said on Thursday it would retaliate against any new punitive steps by the Czech Republic against Russian diplomatic staff as a spy row between the two countries threatened to escalate into a new round of expulsions. Russia ordered out 20 Czech diplomats on Sunday, after Prague expelled 18 Russians the day before. On Wednesday the Czech Republic demanded that Moscow allow the return of all 20 staff to Moscow by Thursday or face further evictions of its diplomats from Prague.

  • France defends Chad military takeover as needed to ensure stability

    France's foreign minister on Thursday defended a military takeover in Chad despite objections from the opposition there, saying it was necessary for security amid "exceptional circumstances". The son of Chad's slain leader Idriss Deby took over as president and armed forces commander on Wednesday and dissolved the government and parliament as rebel forces threatened to march on the capital. Under the constitution, the speaker of the National Assembly should have become interim president.

  • More 5% deposit mortgages unveiled by lenders in boost to first-time buyers

    Metro Bank and Cambridge Building Society have announced new deals.

  • U.S. Futures Fluctuate as Virus Saps Reflation Bet: Markets Wrap

    (Bloomberg) -- U.S. futures fluctuated as investors weighed reflation bets against the outlook for earnings and a resurgence in virus cases across the globe. Treasury yields steadied near a five-week low.Underperformance in contracts on the Russell 2000 Index signalled the rotation toward growth-friendly cyclical stocks was slowing. The benchmark U.S. 10-year yield fell below its 50-day moving average for the first time since November. Concerns are mounting that a flare-up in coronavirus cases could derail the global growth rebound after investors have gone all-in on trades that benefit from re-opening economies including small-cap stocks. They’re also searching for clues in corporate results on the speed of the recovery.“While certainly investors have priced in a lot in terms of normalization in certain segments of the market, I still think that there is room to run,” Erin Browne, Pacific Investment Management Co. multi-asset strategies portfolio manager, said on Bloomberg TV.First-quarter earnings have erred on the upside, with S&P 500 showing a 5% revenue surprise and 38% earnings surprise across 83 earnings reports, according to Saxo Bank. Among closely-watched reports, results from chipmaker Intel Corp. are due Thursday.Nestle SA led European stocks 0.6% higher after sales at the food giant grew more than twice the rate analysts expected amid a return to dining out.The pace of the global rebound will be under the lens of European Central Bank policymakers delivering their latest statement Thursday. The Bank of Canada became the first major central bank this week to signal it will pare back asset purchases and move up its expected timeline for potential rate hikes.The euro was slightly higher against the dollar before the ECB meeting, with no changes expected to the central bank’s plans to accelerate asset purchases until June to rekindle growth.Meanwhile, oil added to losses with an increase in U.S. crude inventories compounding concerns around a choppy global demand recovery.Here are some key events to watch this week:European Central Bank rate decision and President Christine Lagarde briefing on Thursday.U.S. releases new home sales data Friday.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • Pete Bennett hits back after being accused of 'cashing in' after Nikki Grahame's death

    Bennett and Grahame dated after they met on 'Big Brother'.

  • Stacey Dooley Explains Why Marriage Isn't On The Cards For Her And Kevin Clifton

    “I can’t think of anything worse than being a tradwife."

  • Your favourite running app might be putting your privacy at risk

    Some of our most popular fitness apps still fall behind when it comes to privacy, researchers say

  • Uniqlo x JW Anderson is here: The affordable collab for summer staples

    Now it's time to book a pub garden.

  • Options and Murex Celebrate Long-Term Partnership in Delivering MX.3 as a SaaS Solution

    Options Technology empowers Murex MX.3 through its highly secure, enterprise-grade SaaS-enabled Managed Apps platform.

  • Gorman-Rupp Reports First Quarter 2021 Financial Results

    The Gorman-Rupp Company (NYSE: GRC) reports financial results for the first quarter ended March 31, 2021.

  • What the European Super League's collapse means for JPMorgan

    JPMorgan was lined up to be the main financier of the Super League, promising to write a 23-year loan worth over €3bn to fund the creation of the competition.

  • 11 best fire pits for evenings in the garden

    Whether you’re going camping or having a barbecue at home, ensure you have one of these essentials

  • Germany earns two billion euros with its debt in first quarter - document

    Germany earned roughly 2 billion euros ($2.4 billion) from issuing new bonds in the first quarter alone as negative yields continue to push down Berlin's overall debt servicing costs to record lows, a finance ministry document showed on Thursday. The lower-than-expected borrowing costs are enabled by the European Central Bank's loose monetary policy and Germany's international reputation as a fiscally reliable country, resulting in negative interest rates even for longer maturities. In a letter seen by Reuters following a parliamentary request, Deputy Finance Minister Sarah Ryglewski told opposition lawmaker Fabio De Masi that the government issued capital market instruments in 20 auctions on 18 dates in the first three months of 2021 to finance the federal budget and special funds.

  • 2021 Global Exosome Market Size, Forecast, Trials and Trends, Featuring Profiles of 107 Competitors Including Abbexa, Ltd., Abnova, Aruna Bio and Tavec Pharma

    Dublin, April 22, 2021 (GLOBE NEWSWIRE) -- The "The Global Exosome Market - Market Size, Forecast, Trials, and Trends, 2021" report has been added to ResearchAndMarkets.com's offering. Exosome-related technologies have been developing rapidly over the past few years and substantial growth is expected for the market as they get integrated into the fields of liquid biopsy, precision medicine and regenerative medicine. In particular, cancer derived exosomes influence the invasive potential of cells by regulating angiogenesis, metastasis, and immunity, making them an extremely useful source of biomarkers for use in cancer detection, diagnosis, and therapeutic selection. Exosomes are extracellular vesicles (EVs) of endosomal origin that range in size between 30 and 100 nanometers. Exosomes are secreted by a wide range of cells, since virtually all living cells utilize exosome-mediated communication. Exosomes carry cell-specific cargos of proteins, lipids, and nucleic acids that are selectively taken up by recipient cells. The cargo contained within exosomes can offer prognostic information for range of diseases - including cardiovascular, renal, neurodegenerative, and metabolic diseases - as well as cancer. Researchers investigating exosome biomarkers have discovered, identified, and reported the presence of hundreds of biomolecules within the lumen of exosomes. This discovery has compelled a rapid rise in exosome-related cancer biomarker research, including the use of exosomes for the detection, monitoring, and treatment of a diverse range of oncologic conditions. Importantly, exosomes are present within a diverse range of biofluids, including serum, plasma, urine, seminal fluid, CSF, saliva, tears and breast milk. For this reason, exosome-based diagnostics are minimally invasive, offering ease of use and speed of detection. Exosomes can also act as prognostic indicators and predictors of a patient's response to a specific course of treatment. Exosomes are also being explored for their use as cell-free therapeutics. For example, if a patient has a disease caused by a missing or defective protein or microRNA, the patient's exosomes can be isolated, modified with the appropriate siRNA or protein and then injected back into the patient for treatment. There are also many approaches being researched for creating drug-loaded exosomes. Furthermore, exosomes can often exert powerful effects. For example, mesenchymal stem cell (MSC) derived exosomes have the capacity to suppress inflammation, prevent scar tissue formation, and mediate a healthy immune response. For these reasons, exosomes have gone from being overlooked to rapidly gaining momentum as a novel strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering cells to patients. Although exosomes were discovered more than 30 years ago, it was not until recently that the scientific community began to give credit to exosomes for a range of promising traits. Fifteen years ago in 2006, there were only 76 articles published about exosomes on PubMed.gov. Today, there an astounding 17,850 articles published about exosomes on PubMed.gov, of which the vast majority were released in the past five years. When exosome publications are analyzed, U.S. authors have published approximately 40% of the articles and China comes in second place. When the term "exosome" is searched in the scientific literature, Dr. Susanne Gabrielsson from the Karolinska Institutet in Sweden is the leading author. When the term "extracellular vesicles" is searched, Unicyte AG, a regenerative medicine unit of Fresenius Medical Care, takes the lead. Headquartered in Switzerland, the company has published more than 100 papers on exosomes and extracellular vesicles in combination with Professor Giovanni Camussi. This global market report explores growing demand for exosome therapeutics, diagnostics, research tools, and manufacturing technologies. It reveals trend rate data for exosome patents, grants, scientific publications, and clinical trials and highlights information about exosome industry partnerships, merger and acquisition (M&A) activity, and financing events. It features company profiles for 107 global competitors from across the exosome marketplace. Importantly, it presents market size determinations by market segment with forecasts through 2028. Today in 2021, the exosomeindustry is witnessing: A surging number of scientific papers investigating exosomes and their applicationsRising numbers of clinicals trials investigating exosome therapeutics and diagnosticsSwelling appetite among investors for exosome technologyAn increasingly competitive IP environmentA diverse range of co-development partnershipsProliferating numbers of exosome competitors in all major life science markets worldwide Key Topics Covered: 1. REPORT OVERVIEW 2. EXOSOMES: AN OVERVIEW 3. EXOSOME RESEARCH 4. EXOSOMES: CLINICAL TRIALS LANDSCAPE 5. CURRENT STATUS OF EXOSOME MANUFACTURING 6. CURRENT STATUS OF EXOSOME INDUSTRY 7. EXOSOME ISOLATION APPROACHES 8. EXOSOME ENGINEERING: A NEW PLATFORM 9. MSC-DERIVED EXOSOMES IN REGENERATIVE MEDICINE 10. DIAGNOSTIC APPLICATIONS OF EXOSOMES 11. THERAPEUTIC APPLICATIONS OF EXOSOMES 12. APPLICATIONS OF EXOSOMES IN VACCINE DEVELOPMENT 13. EXOSOME RESEARCH TOOLS 14. EXOSOME MARKET ANALYSIS 15. PROFILES OF EXOSOME MARKET COMPETITORS 101 BioAbbexa, Ltd.AbnovaAdipomics, Inc.Aegle TherapeuticsAethlon Medical, Inc.AgeX Therapeutics, Inc.Alexerion Biotech Corp.AMS Biotechnology, Ltd. (AMSBIO)Anjarium Biosciencesantibodies-online GmbHAposcience AGAruna BioAvalon GloboCare Corp.Aviva Systems BiologyAzymus TherapeuticsBARD1 Life Sciences, Ltd.Beckman Coulter Life SciencesBio-TechneBioCat GmbHBioFluidicaBiological Dynamics, Inc.Biorbyt, Ltd.BioRegenerative Sciences, Inc.BioVision, Inc.BrainStorm Cell TherapeuticsBreStem Therapeutics, Inc.Capricor TherapeuticsCD BioparticlesCell Care TherapeuticsCell Factory BVBA/Esperite NVCell Guidance Systems, Ltd.Cellarcus Biosciences, Inc.CiloaClara BiotechCodiak BiosciencesCreative BioarrayCreative BiolabsCreative Medical Technology Holdings, Inc.Creative ProteomicsCusabio Technology LLCDirect BiologicsDLdevelopEVerZomEvomic Science, LLCEvox Therapeutics, Ltd.ExBiome BVExerkine Corp.ExoCan Healthcare Technologies, Pvt. Ltd.ExoCoBio, Co., Ltd.Exogenus TherapeuticsEXoPERTExopharmExosome Diagnostics, Inc.Exosome SciencesExosomePlusExosomics S.p.AExoVectoryGenWay Biotech, Inc.Guardant Health, Inc.HansaBioMed Life Sciences, Ltd.Hitachi Chemical Diagnostics, Inc.ILIAS Biologics, Inc.Innocan Pharma CorporationInnovex Therapeutics, S.L.Invent Biotechnologies, Inc.Invitrx TherapeuticsIzon Science, Ltd.Kimera Labs, Inc.Leading Biology, Inc.LifeSpan BioSciences, Inc.Lonza Group Ltd.Mantra BioMDimuneMiltenyi Biotec B.V. & Co. KGmiR ScientificMursla, Ltd.MyBioSource, Inc.NanoSomix, Inc.NanoView BiosciencesNeurExo SciencesNew England Peptide, Inc.Norgen Biotek Corp.Novus Biologicals, LLCnRichDx, Inc.Oasis Diagnostics Corp.OmniSpirant LimitedOriGene Technologies, Inc.Paracrine Therapeutics, Pvt. Ltd.QIAGENReNeuronRoosterBio, Inc.Stemcell Medicine, Ltd.System Biosciences, LLCTavec PharmaTheoria Science, Inc.Thermo Fisher ScientificTransGen Biotech, Co., Ltd.TriArm Therapeutics, Co., Ltd.United Therapeutics Corp.Versatope TherapeuticsVesigen Therapeutics, Inc.VivaZome Therapeutics, Pvt. Ltd.Xollent BiotechXOStem, Inc.YMIR Genomics LLC For more information about this report visit https://www.researchandmarkets.com/r/wfb5ah About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

  • Poste Italiane: la raccomandata si può spedire anche online e da App

    In collaborazione con Postenews Con Poste Italiane è possibile spedire una raccomandata anche online e da App. Il servizio, cresciuto dell’82% nel corso della pandemia da Covid-19, consente di spedire documenti digitali in Italia e nel mondo direttamente sul sito poste.it oppure tramite l’App Ufficio Postale. Poste Italiane provvede a stampa (fronte/retro, in bianco e nero o a colori), imbustamento e consegna, emettendo una ricevuta dello stesso valore legale di quella rilasciata dall'ufficio postale. La raccomandata online mette a disposizione una serie di funzionalità aggiuntive quali: la rubrica degli indirizzi, la possibilità di effettuare invii multipli della stessa raccomandata (fino a un massimo di 200 destinatari con una sola operazione), l’archivio delle spedizioni disponibile per 6 anni. In più il destinatario, se attiva il servizio Ritiro Digitale, in caso di mancata consegna per sua assenza può ritirare la raccomandata in modalità digitale su poste.it. Il cliente può monitorare lo stato dell’invio tramite l'archivio personale delle spedizioni, il servizio “cerca spedizioni” sul sito poste.it, il numero verde 803.160, l’App Ufficio Postale. Per informazioni: https://www.poste.it/gamma/spedisci-online.html Per maggiori approfondimenti: https://www.postenews.it/2021/01/12/app-e-servizi-online-cosi-lecosistema-digitale-di-poste-aiuta-a-contrastare-il-virus/

  • Terna, entro 2030 taglio 30% emissioni CO2

    Terna, in occasione della Giornata Mondiale della Terra, lancia il suo nuovo piano di riduzione della CO2: entro il 2030 la società che gestisce la rete elettrica di trasmissione nazionale si impegna a tagliare di circa il 30% rispetto ai livelli del 2019 le proprie emissioni inquinanti, per un valore pari a circa 460 mila tonnellate annue di anidride carbonica equivalente in meno in atmosfera. Coerentemente con la propria strategia di sostenibilità e in linea con quanto stabilito nell’Accordo di Parigi, Terna ha adottato uno Science-Based Target (Sbt) impegnandosi concretamente a ridurre le emissioni delle proprie attività, per una transizione ecologia verso un’economia low carbon. Le azioni che Terna ha deciso di mettere in campo nel suo piano “science-based” - presentato con il supporto della società di consulenza Carbonsink - riguardano, nello specifico, l’accelerazione degli investimenti per lo sviluppo della rete elettrica per favorire la piena integrazione delle fonti di energia rinnovabile e ridurre le perdite di rete, attività per l’efficientamento dei consumi elettrici ed energetici, il contenimento delle perdite di gas climalteranti (SF6) utilizzati in alcuni impianti, il taglio delle emissioni della flotta aziendale e in generale quelle legate alla mobilità dei dipendenti. Inoltre, l’azienda ha deciso di avviare interventi di tutela e valorizzazione ambientale, tra cui programmi di piantumazione di alberi sul territorio italiano in collaborazione con la società AzzeroCO2 oltre a un progetto di economia circolare traguardato al 2030. Attualmente sono solo 10 le aziende italiane sulle oltre mille complessive a livello globale che hanno sottoscritto un Sbt con obiettivi validati. I target adottati da Terna, coerenti con lo scenario definito “well below 2°C” ovvero conformi alle direttive raccomandate dagli scienziati per mantenere l’aumento delle temperature globali al di sotto di specifici limiti, saranno esaminati e valutati dalla Science Based Targets Initiative (Sbti). L’istituzione, nata dalla collaborazione tra Climate Disclosure Project (CDP), United Nations Global Compact (UNGC), World Resources Institute (WRI) e WWF, attesta l’impegno da parte delle aziende nella riduzione delle emissioni di gas a effetto serra e favorisce azioni ambiziose nella lotta ai cambiamenti climatici nel settore privato per limitare l’innalzamento della temperatura a livello globale in linea con i target fissati dall'Accordo di Parigi sul clima del 2015 e con quanto ritenuto necessario dalle più recenti evidenze della scienza in materia di ambiente. La centralità della sostenibilità nel business si concretizza nel Piano Industriale 2021-2025, nel quale Terna ha previsto 8,9 miliardi di euro di investimenti per lo sviluppo e l’ammodernamento della rete elettrica nazionale, il livello più alto mai previsto da Terna per il nostro Paese, e che in base ai criteri della Tassonomia Europea per il 95% sono considerati per loro natura sostenibili. Attraverso la definizione di specifici obiettivi, finalizzati alla creazione di valore nel medio-lungo termine, Terna ha definito target articolati in quattro dimensioni – Risorse umane; Stakeholder e territorio; Integrità, responsabilità e trasparenza; Ambiente – e declinati in 14 obiettivi cui afferiscono oltre 120 attività distribuite nell’intero arco temporale di Piano. Nell’attuale scenario di crisi pandemica, Terna ha recentemente rinnovato il proprio impegno verso i 10 Principi del Global Compact e i 17 Sdgs dell’Onu per contribuire fattivamente allo sviluppo sostenibile e rafforzando il suo ruolo centrale quale regista e abilitatore del sistema energetico italiano, principale realtà in grado di accompagnare il paese verso il raggiungimento degli obiettivi europei di “emissioni nette zero” entro il 2050. Un impegno certificato anche dalla conferma, per il terzo anno consecutivo, al primo posto mondiale nel settore Electric Utilities del Dow Jones Sustainability World Index e il riconoscimento da parte di Seal (Sustainability, Environmental Achievement & Leadership) Business Sustainability Awards tra le 50 aziende più sostenibili a livello globale. La strategia di Terna prosegue con l’impegno a minimizzare sempre più l’impatto visivo e paesaggistico delle infrastrutture elettriche attraverso l’utilizzo di soluzioni innovative e la rimozione nell’arco di Piano di circa 500 km di linee rese obsolete dai nuovi investimenti di sviluppo della rete.